Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Syndax Pharmaceuticals (SNDX) Shares Issued (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Shares Issued for 12 consecutive years, with $7.5 million as the latest value for Q1 2026.

For Q1 2026, Shares Issued rose 1837.66% year-over-year to $7.5 million; the TTM value through Mar 2026 reached $19.2 million, up 194.41%, while the annual FY2025 figure was $12.1 million, 51.72% up from the prior year.
Shares Issued hit $7.5 million in Q1 2026 for Syndax Pharmaceuticals, down from $11.2 million in the prior quarter.
Across five years, Shares Issued topped out at $162.0 million in Q4 2022 and bottomed at -$4.1 million in Q4 2023.
Average Shares Issued over 5 years is $11.2 million, with a median of $1.9 million recorded in 2024.
Year-over-year, Shares Issued crashed 185.19% in 2023 and then soared 1837.66% in 2026.
Syndax Pharmaceuticals' Shares Issued stood at $162.0 million in 2022, then tumbled by 102.53% to -$4.1 million in 2023, then soared by 176.45% to $3.1 million in 2024, then soared by 256.96% to $11.2 million in 2025, then plummeted by 33.42% to $7.5 million in 2026.
According to Business Quant data, Shares Issued over the past three periods came in at $7.5 million, $11.2 million, and $465000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.